In the anal AD group, 11.1% (5 of 45) of patients had druggable GAs with approved drugs, such as olaparib and niraparib for BRCA2, pemigatinib for FGFR2, and pembrolizumab for TMB-high status. The gene discussed is FGFR2; the disease is Alzheimer disease.